Clinical analysis of multiple myeloma in patients over 80 years old: A report of 11 cases
-
摘要:
目的 探讨80岁以上高龄老年多发性骨髓瘤的临床特点。 方法 对本院2000年12月至2013年12月收治的11例80岁以上多发性骨髓瘤患者的临床资料进行回顾性分析。 结果 11例老年多发性骨髓瘤平均年龄为（83.5±3.4）岁，所有患者至少合并2个以上其他基础性疾病。DS分期Ⅲ期为8例、ISS分期Ⅲ期7例。共10例患者接受了个体化的治疗方案，无效进展3例，CR 1例，PR 3例，MR 4例。中位生存28（2~97）个月，1、2、3年生存率分别为72.7%、54.5%、36.3%。因疾病进展导致死亡的6例，疾病稳定期因肺炎死亡3例、AMI死亡2例。 结论 高龄老年多发性骨髓瘤分期较晚，临床表现不典型。治疗应根据患者情况进行个体化的治疗，感染和心血管并发症较常见且是主要死亡原因。经过个体化治疗及有效的支持治疗，生存期得到明显延长，尤其是Ⅰ~Ⅱ期患者经个体化治疗后生存期可接近5年。 Abstract:Objective This study aimed to explore clinical features of multiple myeloma in patients over 80 years old. Methods We retrospectively analyzed 11 cases of multiple myeloma over 80 years old, which were diagnosed from 2000 to 2013 in our hospital. Results The mean age was 83.5 years. All patients had more than two complicated diseases, and the performance status was poor in the majority of the patients. Ten cases received individualized treatments. The results showed that three patients had progressed, one patient achieved complete remission, three patients achieved partial remission, and four patients achieved minor remission. Median survival time was 28 months. The causes of death included six progressed myelomas, three pneumonias, and two acute myocardial infarctions. Conclusion Patients aged 80 years old with myeloma are often at a late stage. Treatment should be individualized based on patient status. Survival time was evidently prolonged in very elderly patients with MM after individualized treatments, particularly in patients in stages Ⅰ and Ⅱ. -
Key words:
- elderly /
- multiple myeloma /
- individualized treatment
-
表 1 11例多发性骨髓瘤患者基本特征
Table 1. Basic characteristics of 11 patients with multiple myeloma
表 2 11例多发性骨髓瘤患者临床特征
Table 2. Clinical characteristics of 11 patients with multiple myeloma
表 3 11例多发性骨髓瘤治疗方案、疗效及生存期
Table 3. Treatment regimen, efficacy, and survival period of 11 patients with multiple myeloma
-
[1] Palumbo A, Anderson K. Multiple myeloma[J]. N Engl J Med, 2011, 364(11):1046-1060. doi: 10.1056/NEJMra1011442 [2] The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group[J]. Br J Haematol, 2003, 121(5):749-757. doi: 10.1046/j.1365-2141.2003.04355.x [3] 中国多发性骨髓瘤工作组.中国多发性骨髓瘤诊治指南(2013年修订)[J].中华内科杂志, 2013, 52(9):791-795.] http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnk201309028The Chinese myeloma working group. Guideline for diagnosis and management of multiple myeloma(2013) [J]. Chinese Journal of Internal Medicine, 2013, 52(9):791-795.[ http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnk201309028 [4] Kristinsson SY, Anderson WF, Landgren O. Improvel long-term survival in multiple myeloma up to the age of 80 years[J]. Leukemia, 2014, 28(6):1346-1348. doi: 10.1038/leu.2014.23 [5] Ludwig H, Bolejack V, Crowley J, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma[J]. J Clin Oncol, 2010, 28(9):1599-1605. doi: 10.1200/JCO.2009.25.2114 [6] Nilsson T, Lenhoff S, Turesson I, et al. Cytogenetic features of multiple myeloma: Impact of gender, age, disease phase, culture time, and cytokine stimulation[J]. Eur J Haematol, 2002, 68(6):345-353. doi: 10.1034/j.1600-0609.2002.00724.x [7] Rajkumar SV, Blood E, Vesole D, et al. PhaseⅢclinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group[J]. J Clin Oncol, 2006, 24(3):431-436. doi: 10.1200/JCO.2005.03.0221 [8] Gay F, Larocca A, Wijermans P, et al. Complete responsecorrelates with long-term progression-free and overall survival in elderlymyeloma treated with novel agents: analysis of 1175 patients[J]. Blood, 2011, 117(11):3025-3031. doi: 10.1182/blood-2010-09-307645 [9] Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials[J]. Blood, 2011, 118(5):1239-1247. doi: 10.1182/blood-2011-03-341669 [10] Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)[J]. Leukemia, 2014, 28(3):525-542. doi: 10.1038/leu.2013.350 [11] Yaqub S, Ballester G, Ballester O. Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials[J]. Cancer Invest, 2013, 31(8):529-537. doi: 10.3109/07357907.2013.840382 [12] Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) [J]. Blood, 2011, 118(17):4519-4529. doi: 10.1182/blood-2011-06-358812 [13] Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial[J]. J Clin Oncol, 2009, 27(22):3664-3670. doi: 10.1200/JCO.2008.21.0948 [14] Offidani M, Leoni P, Bringhen S, et al. Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study[J]. Leuk Lymphoma, 2010, 51(8): 1444-1449. doi: 10.3109/10428194.2010.486878 -
点击查看大图
表(3)
计量
- 文章访问数: 87
- HTML全文浏览量: 124
- PDF下载量: 4
- 被引次数: 0
下载:
